Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accounts Payables: 2019-2025

Historic Accounts Payables for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $9.6 million.

  • Avidity Biosciences' Accounts Payables fell 80.60% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 80.60%. This contributed to the annual value of $8.5 million for FY2024, which is 75.36% down from last year.
  • Latest data reveals that Avidity Biosciences reported Accounts Payables of $9.6 million as of Q3 2025, which was up 145.94% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Accounts Payables ranged from a high of $54.2 million in Q1 2025 and a low of $3.9 million during Q2 2025.
  • For the 3-year period, Avidity Biosciences' Accounts Payables averaged around $30.5 million, with its median value being $33.9 million (2023).
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 140.71% in 2022, then plummeted by 90.44% in 2025.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Accounts Payables stood at $14.1 million in 2021, then soared by 131.25% to $32.6 million in 2022, then rose by 5.43% to $34.3 million in 2023, then slumped by 75.36% to $8.5 million in 2024, then plummeted by 80.60% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q3 2025, $3.9 million for Q2 2025, and $54.2 million during Q1 2025.